Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 84

Results For "RSE"

1403 News Found

Nuance Pharma announces the completion of dosing for all NTM-001 Phase 1 clinical study
Diagnostic Center | July 27, 2022

Nuance Pharma announces the completion of dosing for all NTM-001 Phase 1 clinical study

The NTM-001 Phase I clinical study is expected to be completed by the end of 2022


AstraZeneca collaborates with – Indian Society of Nephrology to launch CKD Academy
News | July 27, 2022

AstraZeneca collaborates with – Indian Society of Nephrology to launch CKD Academy

AstraZeneca and Indian Society of Nephrology aim to help clinicians and healthcare practitioners to provide holistic kidney care to their patients.


Merck opens microbiology application lab in Jigani, Bengaluru
Diagnostic Center | July 24, 2022

Merck opens microbiology application lab in Jigani, Bengaluru

Merck’s first microbiology application and training lab in India


Roche launches Elecsys HCV Duo immunoassay for hepatitis C virus
News | July 20, 2022

Roche launches Elecsys HCV Duo immunoassay for hepatitis C virus

Elecsys HCV Duo is the first commercially available immunoassay that allows the simultaneous and independent determination of the hepatitis C virus (HCV) antigen and antibody status.


Pharma manufacturer 'Gansons' turns 75
News | July 18, 2022

Pharma manufacturer 'Gansons' turns 75

Gansons is based in Thane (Maharashtra, India) with global representation in UK, USA, UAE, Central Asia, South Asia and South-East Asia.


Glaucoma Research Foundation launches catalyst for a to prevent and cure neurodegeneration
News | July 18, 2022

Glaucoma Research Foundation launches catalyst for a to prevent and cure neurodegeneration

Groundbreaking collaborative research program will explore common characteristics of glaucoma, alzheimer's


CEPI funds consortium led by CPI to advance Caltech’s new all-in-one coronavirus vaccine
News | July 15, 2022

CEPI funds consortium led by CPI to advance Caltech’s new all-in-one coronavirus vaccine

Up to $30m funding will be provided to advance an innovative vaccine technology that could protect against current and future SARS-CoV-2 variants and other SARS-like Betacoronaviruses.


Novavax statement on EMA Nuvaxovid label update related to allergic reaction
News | July 15, 2022

Novavax statement on EMA Nuvaxovid label update related to allergic reaction

Novavax’ clinical development program reported no severe allergic reactions